Clinical Trials Logo

Cavernous Angiomas clinical trials

View clinical trials related to Cavernous Angiomas.

Filter by:
  • Completed  
  • Page 1

NCT ID: NCT00783523 Completed - Clinical trials for Arteriovenous Malformations

Influence of MMP on Brain AVM Hemorrhage

Start date: March 2008
Phase: Phase 1
Study type: Interventional

Brain vascular malformations, including arteriovenous malformations (AVM), cavernous malformations (CVM) and aneurysms, are a source of life-threatening risk of intracranial hemorrhage. The etiology and pathogenesis are unknown. There is no medical therapy presently available. Prevention of spontaneous intracerebral hemorrhage (ICH) is the primary reason to treat brain vascular malformations. The goal of this study is to: begin pilot studies to lay the groundwork for future clinical trials to develop medical therapy to decrease ICH risk. Matrix metalloproteinases (MMPs) regulate the extracellular matrix in association with various hemorrhagic brain disorders. MMP-9 has been most consistently associated with vascular wall instability and hemorrhagic brain disorders. Doxycycline, a non-specific MMP inhibitor, may enhance vascular stability, thus reducing the risk of spontaneous hemorrhage in brain vascular malformations by decreasing MMP-9 activity.